Chemomab Therapeutics Ltd DRC
$ 1.93
7.22%
07 Aug - close price
- Market Cap 14,142,400 USD
- Current Price $ 1.93
- High / Low $ 2.04 / 1.83
- Stock P/E N/A
- Book Value 1.49
- EPS -1.12
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.71 %
- 52 Week High 4.12
- 52 Week Low 1.35
About
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-03 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.003 | -0.003 | -0.004 | -0.02 | -0.14 | -0.008 | -0.04 | 0.05 | -0.06 | -0.2654 | -0.07 | -0.14 |
| Estimated EPS | 0 | -0.01 | -0.04 | -0.04 | -0.2 | -0.01 | -0.04 | -0.04 | -0.06 | -0.02 | -0.08 | -0.16 |
| Surprise | -0.003 | 0.007 | 0.036 | 0.02 | 0.06 | 0.002 | 0 | 0.09 | 0 | -0.2454 | 0.01 | 0.02 |
| Surprise Percentage | None% | 70% | 90% | 50% | 30% | 20% | 0% | 225% | 0% | -1227% | 12.5% | 12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2026-08-10 15:40:21
Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive power over these shares, and his ownership remains below the 5% threshold for passive investment.
2026-08-08 01:10:19
Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the next quarter's EPS projected at USD -0.15.
2026-08-06 14:11:19
Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher Medicine Corporation valued at $100 million. Despite these risks, Chemomab has reported positive Phase 2 clinical trial results for its lead product candidate, nebokitug, in treating primary sclerosing cholangitis (PSC) and is advancing towards Phase 3.
2026-08-02 03:41:09
This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for various financial indicators like EPS, net profit, assets, liabilities, and equity. The report also includes an analyst rating of "STRONG BUY" and addresses frequently asked questions regarding key financial figures from the FY2025 earnings report.
2026-07-29 22:51:17
Chemomab Therapeutics Ltd (CMMB) closed at $1.540, up 7.69%, with a market capitalization of $44.35M. Analysts have given the company a "Strong Buy" rating with a target price of $15.00, suggesting a significant upside. The company is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for fibrotic and inflammatory diseases.
2026-07-28 10:11:27
This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. The analysis concludes with a general signal of "Neutral" based on these technical factors.
